JP2005538093A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005538093A5 JP2005538093A5 JP2004523295A JP2004523295A JP2005538093A5 JP 2005538093 A5 JP2005538093 A5 JP 2005538093A5 JP 2004523295 A JP2004523295 A JP 2004523295A JP 2004523295 A JP2004523295 A JP 2004523295A JP 2005538093 A5 JP2005538093 A5 JP 2005538093A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tetrathiomolybdate
- tetraalkylammonium
- compound
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 70
- -1 tetraalkylammonium tetrathiomolybdate compound Chemical class 0.000 claims 26
- 239000003814 drug Substances 0.000 claims 13
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 claims 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 9
- 229910052802 copper Inorganic materials 0.000 claims 9
- 239000010949 copper Substances 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 5
- 150000003752 zinc compounds Chemical class 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 claims 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims 2
- 108010075016 Ceruloplasmin Proteins 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000005207 tetraalkylammonium group Chemical group 0.000 claims 2
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims 1
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- 102400001047 Endostatin Human genes 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 125000005210 alkyl ammonium group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- ZKKLPDLKUGTPME-UHFFFAOYSA-N diazanium;bis(sulfanylidene)molybdenum;sulfanide Chemical compound [NH4+].[NH4+].[SH-].[SH-].S=[Mo]=S ZKKLPDLKUGTPME-UHFFFAOYSA-N 0.000 claims 1
- 239000002596 immunotoxin Substances 0.000 claims 1
- 229940051026 immunotoxin Drugs 0.000 claims 1
- 231100000608 immunotoxin Toxicity 0.000 claims 1
- 230000002637 immunotoxin Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 claims 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 claims 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960001124 trientine Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39780402P | 2002-07-23 | 2002-07-23 | |
| PCT/US2003/022914 WO2004009072A2 (en) | 2002-07-23 | 2003-07-23 | Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005538093A JP2005538093A (ja) | 2005-12-15 |
| JP2005538093A5 true JP2005538093A5 (https=) | 2006-09-07 |
Family
ID=30771119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004523295A Pending JP2005538093A (ja) | 2002-07-23 | 2003-07-23 | 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7888389B2 (https=) |
| EP (1) | EP1539131A4 (https=) |
| JP (1) | JP2005538093A (https=) |
| KR (1) | KR20050025976A (https=) |
| CN (1) | CN1688303A (https=) |
| AU (1) | AU2003261222B2 (https=) |
| BR (1) | BR0312845A (https=) |
| CA (1) | CA2493341A1 (https=) |
| EA (1) | EA008683B1 (https=) |
| GE (1) | GEP20074270B (https=) |
| IL (1) | IL166385A0 (https=) |
| MX (1) | MXPA05000875A (https=) |
| NO (1) | NO20050902L (https=) |
| NZ (1) | NZ537896A (https=) |
| WO (1) | WO2004009072A2 (https=) |
| ZA (1) | ZA200501162B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6703050B1 (en) | 1998-09-04 | 2004-03-09 | The Regents Of The University Of Michigan | Methods and compositions for the prevention or treatment of cancer |
| EP1115389B1 (en) * | 1998-09-25 | 2014-03-12 | PhilERA New Zealand Limited | Fructosamine oxidase: antagonists and inhibitors |
| CN1649577A (zh) * | 2002-03-08 | 2005-08-03 | 普罗特米克斯公司 | 预防和/或治疗心血管疾病和/或相关的心衰 |
| US20070292533A1 (en) * | 2002-05-24 | 2007-12-20 | Regents Of The University Of Michigan | Copper lowering treatment of autoimmune diseases |
| US20070248689A1 (en) * | 2002-05-24 | 2007-10-25 | Regents Of The University Of Michigan | Copper lowering treatment of inflammatory and fibrotic diseases |
| US7189865B2 (en) * | 2002-07-23 | 2007-03-13 | Attenuon, Llc | Thiomolybdate analogues and uses thereof |
| GEP20074270B (en) | 2002-07-23 | 2007-12-25 | Univ Michigan | Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| CA2875522A1 (en) | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Dosage forms and related therapies |
| RU2002128364A (ru) * | 2002-10-23 | 2004-04-27 | Институт нефтехимического синтеза РАН им. А.В. Топчиева | Способ получения присадки к смазочным материалам (варианты) |
| JP2007516234A (ja) | 2003-05-27 | 2007-06-21 | アテニュオン，リミティド ライアビリティー カンパニー | チオタングステン酸（塩）アナログ及びその使用 |
| WO2005082382A1 (en) * | 2004-02-23 | 2005-09-09 | Attenuon Llc | Formulations of thiomolybdate or thiotungstate compounds and uses thereof |
| AU2005217623A1 (en) * | 2004-02-24 | 2005-09-09 | Attenuon Llp | Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents |
| PT1778618E (pt) | 2004-07-19 | 2014-03-04 | Philera New Zealand Ltd | Síntese de trietilenotetraminas |
| WO2006044779A1 (en) * | 2004-10-14 | 2006-04-27 | Northwestern University | Detection and treatment of renal cancer |
| EP2117315A1 (en) * | 2007-02-21 | 2009-11-18 | SSV Therapeutics, Inc. | Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids |
| WO2009009622A2 (en) * | 2007-07-09 | 2009-01-15 | Pipex Pharmaceuticals, Inc. | Pharmaceutical compositions, including attm, and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases |
| US20100312139A1 (en) * | 2009-06-04 | 2010-12-09 | Board Of Regents Of The University Of Texas System | Method for Identifying Mammals at Risk for Elevated intracranial Pressure |
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| US20160220500A1 (en) * | 2014-11-14 | 2016-08-04 | Kent State University | Targeting Intracellular Copper Ions for Inhibiting Angiogenesis Using Nanoparticles of Ternary Inorganic Metal Sulfide M1M2S4 (M1, independently, is Mg, Ca, Mn, Fe, or Zn; M2 = Mo or W) Compounds to Treat Metastatic Cancer |
| JP6889116B2 (ja) | 2015-02-03 | 2021-06-18 | カドモン ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 安定トリエンチン製剤 |
| MX2020006284A (es) * | 2017-12-04 | 2021-04-12 | Alexion Pharma Int Operations Unlimited Company | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| EP4225386B1 (en) | 2020-10-07 | 2024-10-30 | CTI Vascular AG | Bioactivatable devices and related methods |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909541A (en) | 1955-01-07 | 1959-10-20 | Inst Francais Du Petrole | Nitrogenous thiomolybdates |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4343746A (en) | 1980-12-10 | 1982-08-10 | Gulf Research & Development Company | Quaternary ammonium thiomolybdates |
| US4762705A (en) | 1981-11-10 | 1988-08-09 | Adolf W. Schwimmer | Cancer therapy with interferon |
| US4952607A (en) | 1982-05-27 | 1990-08-28 | International Copper Research Association, Inc. | Copper complex for treating cancer |
| US4430443A (en) * | 1982-07-20 | 1984-02-07 | Exxon Research And Engineering Co. | Supported carbon-containing molybdenum and tungsten sulfide catalysts, their preparation and use |
| US4766226A (en) | 1984-02-01 | 1988-08-23 | Smithkline Beckman Corporation | Antitumor pharmaceutical compositions and methods for treating tumors employing α,ω-bis(disubstitutedphosphino)hydrocarbon derivatives or [α, ω-bis(disubstitutedphosphino)hydrocarbon] di |
| ATE80801T1 (de) | 1984-12-18 | 1992-10-15 | Clark Pharma Dev | Antitumorzusammensetzungen enthaltend ein reaktionsprodukt zwischen einem cytotoxischen aldehyd und penicillamin und deren verwendung zur herstellung von arzneimitteln. |
| GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| US4604278A (en) | 1985-05-17 | 1986-08-05 | Gte Products Corporation | Production of ammonium tetrathiomolybdate |
| US4678667A (en) | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5162231A (en) | 1989-10-25 | 1992-11-10 | Cole Dean A | Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung |
| US5057302A (en) | 1987-02-13 | 1991-10-15 | Abbott Laboratories | Bifunctional chelating agents |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5385933A (en) | 1989-02-27 | 1995-01-31 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the treatment of cancer by use of the copper complex of S-(methylthio)-DL-homocysteine or the L-enantiomorph thereof |
| US5100885A (en) | 1989-08-01 | 1992-03-31 | Johnson Matthey, Inc. | Copper radiosensitizers |
| US5443816A (en) | 1990-08-08 | 1995-08-22 | Rhomed Incorporated | Peptide-metal ion pharmaceutical preparation and method |
| MX172248B (es) | 1989-12-20 | 1993-12-09 | Univ Mexico | Procedimiento para la obtencion de nuevos complejos aminoacidatos de cobre mixtos a base de fenantrolinas feniladas como agentes anticancerigenos |
| US5972922A (en) * | 1990-06-11 | 1999-10-26 | Alcon Laboratories, Inc. | Steroids which inhibit angiogenesis |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| WO1994000118A1 (en) | 1992-06-19 | 1994-01-06 | The University Of Toledo | Production and use of imines of porphyrins |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5565491A (en) | 1994-01-31 | 1996-10-15 | Bristol-Myers Squibb Company | Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation |
| US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
| US5563132A (en) | 1994-06-21 | 1996-10-08 | Bodaness; Richard S. | Two-step cancer treatment method |
| US5583153A (en) | 1994-10-06 | 1996-12-10 | Regents Of The University Of California | Use of taxol in the treatment of rheumatoid arthritis |
| US5527533A (en) | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
| US5970974A (en) | 1995-03-14 | 1999-10-26 | Siemens Aktiengesellschaft | Dosating unit for an ultrasonic atomizer device |
| EP0814860B1 (en) | 1995-03-14 | 1999-11-03 | Siemens Aktiengesellschaft | Ultrasonic atomizer device with removable precision dosating unit |
| US5639757A (en) * | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
| US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
| ES2188261T3 (es) | 1998-09-04 | 2003-06-16 | Univ Michigan | Tiomolibdato asociado a, al menos, un hidrato de carbono y su uso en la prevencion o tratamiento de enfermedades caracterizadas por una vacularizacion aberrante, tales como cancer, degeneracion macular tipo humedo, artritis reumatoides. |
| SI1107795T1 (en) | 1998-09-04 | 2003-06-30 | The Regents Of The University Of Michigan | Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis |
| US6703050B1 (en) | 1998-09-04 | 2004-03-09 | The Regents Of The University Of Michigan | Methods and compositions for the prevention or treatment of cancer |
| WO2003018595A2 (en) * | 2001-08-24 | 2003-03-06 | Maine Medical Center Research Institute | Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto |
| EP1531827A4 (en) * | 2002-05-24 | 2009-07-08 | Univ Michigan | COPPER-REDUCING TREATMENT FOR INFLAMMATORY AND FIBROTIC DISEASES |
| US7189865B2 (en) | 2002-07-23 | 2007-03-13 | Attenuon, Llc | Thiomolybdate analogues and uses thereof |
| GEP20074270B (en) | 2002-07-23 | 2007-12-25 | Univ Michigan | Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
-
2003
- 2003-07-23 GE GEAP20038654A patent/GEP20074270B/en unknown
- 2003-07-23 NZ NZ537896A patent/NZ537896A/en unknown
- 2003-07-23 MX MXPA05000875A patent/MXPA05000875A/es unknown
- 2003-07-23 WO PCT/US2003/022914 patent/WO2004009072A2/en not_active Ceased
- 2003-07-23 CN CNA03820746XA patent/CN1688303A/zh active Pending
- 2003-07-23 CA CA002493341A patent/CA2493341A1/en not_active Abandoned
- 2003-07-23 EP EP03765921A patent/EP1539131A4/en not_active Withdrawn
- 2003-07-23 EA EA200500244A patent/EA008683B1/ru not_active IP Right Cessation
- 2003-07-23 AU AU2003261222A patent/AU2003261222B2/en not_active Expired - Fee Related
- 2003-07-23 JP JP2004523295A patent/JP2005538093A/ja active Pending
- 2003-07-23 KR KR1020057001226A patent/KR20050025976A/ko not_active Ceased
- 2003-07-23 US US10/625,839 patent/US7888389B2/en not_active Expired - Lifetime
- 2003-07-23 BR BR0312845-8A patent/BR0312845A/pt not_active Application Discontinuation
-
2005
- 2005-01-20 IL IL16638505A patent/IL166385A0/xx unknown
- 2005-02-09 ZA ZA200501162A patent/ZA200501162B/xx unknown
- 2005-02-18 NO NO20050902A patent/NO20050902L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005538093A5 (https=) | ||
| WO2004009072B1 (en) | Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies | |
| JPH10509143A (ja) | ２，２′−ジチオ−ビス（エタンスルホネート）（ジメスナ）と組み合わせたシスプラチン組成物 | |
| JP2019515884A5 (https=) | ||
| TW201429473A (zh) | 腫瘤溶解症候群之治療劑及預防劑 | |
| JP2016155826A (ja) | 経口薬物療法のための方法および組成物 | |
| JP5642892B2 (ja) | 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤 | |
| US8664268B2 (en) | Gallium compositions for the treatment of liver cancer and methods of use | |
| US20240130994A1 (en) | Ionic liquid formulations for treating diabetes | |
| CN112567037B (zh) | 治疗或诊断tnf相关炎性疾病的tnf靶向适配体及其用途 | |
| JP7069119B2 (ja) | 医薬組成物 | |
| JP4395368B2 (ja) | 細胞殺傷活性を有するカルシウム塩 | |
| FR2680687A1 (fr) | Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales. | |
| JP2004315470A (ja) | ヨウ化ナトリウム含有製剤 | |
| JP2008518017A (ja) | 相乗的な多機能性組成物の製造方法及び使用方法 | |
| CN116635023A (zh) | 用于治疗糖尿病的离子液体制剂 | |
| CA2986081C (en) | Pharmaceutical formulation for the treatment of inflammatory changes to the rectum | |
| US20060293218A1 (en) | Salicylate therapeutic compound and process for controlled delivery thereof | |
| EP0528076A1 (en) | Use of Mebeverine against non-specific inflammatory bowel disease | |
| WO2024102968A1 (en) | Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap) | |
| CN105541838A (zh) | 一种治疗肾结石的药物组合物 | |
| JPH0254327B2 (https=) | ||
| CN114423435A (zh) | 用于治疗神经变性障碍的CuPTSM | |
| JP2003335703A (ja) | 肥厚性幽門狭窄症の治療薬及び同治療用キット | |
| NZ771802B2 (en) | Pharmaceutical compositions comprising meloxicam |